Parkman Healthcare Partners LLC Has $1.49 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Parkman Healthcare Partners LLC trimmed its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 21.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 903,140 shares of the biopharmaceutical company’s stock after selling 241,506 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Esperion Therapeutics were worth $1,490,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. BOKF NA bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $26,000. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics in the 3rd quarter valued at $27,000. Xponance Inc. acquired a new stake in Esperion Therapeutics during the 2nd quarter valued at $28,000. Sivia Capital Partners LLC bought a new position in Esperion Therapeutics during the second quarter worth $44,000. Finally, National Bank of Canada FI increased its holdings in shares of Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday. Finally, Needham & Company LLC reduced their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th.

Esperion Therapeutics Trading Up 4.8 %

Shares of ESPR opened at $3.25 on Wednesday. The stock has a market capitalization of $640.36 million, a PE ratio of -5.08 and a beta of 1.01. The firm’s 50 day moving average is $2.18 and its 200-day moving average is $2.17. Esperion Therapeutics, Inc. has a 12 month low of $1.35 and a 12 month high of $3.44.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.